Skip to main content

Table 1 Clinical characteristics of studied patients

From: Reduced expression of miR-146a in human bronchial epithelial cells alters neutrophil migration

CharacteristicAll asthmaticsEosinophilica phenotypeNeutrophilicb phenotypePaucigranulocyticc phenotypeControls
n, (%)30 (100)11 (36.7)7 (23.3)12 (40.0)11 (100)
Gender: male/female16/144/75/27/57/4
Age (y), mean ± SD45.6 ± 13.139.8 ± 9.548.1 ± 18.749.3 ± 11.352.2 ± 16.6
Duration of asthma (y), mean ± SD15.0 ± 16.38.3 ± 8.013.9 ± 7.921.8 ± 22.7NA
FEV1 % predicted81.8 ± 24.086.6 ± 22.774.2 ± 32.981.9 ± 20.1111.2 ± 9.6
FEV1 % reversibility7.2 ± 7.26.5 ± 5.46.2 ± 5.78.4 ± 9.53.0 ± 3.5
Positive skin prick test with common allergens n, (%)15 (50.0)4 (36.4)4 (57.1)7 (58.3)NA
Severity of asthma, median (IQR)d4 (1–5)4 (2–4)4 (2–5)4 (1–5)NA
Inhaled glucocorticosteroids (%, average dose μg, [range])96.6, 969 (0–4000)100, 940 (250–2000)100, 929 (500–2000)91.6, 1020
(0–4000)
0
Systemic glucocorticosteroids n, (%)7 (23.3)1 (9.1)4 (57.1)2 (16.7)0
  1. NA not applicable/available
  2. aEosinophilic (E), > 2% of eosinophils and < 3% of neutrophils in BALF
  3. bNeutrophilic (N), < 2% eosinophils and > 3% neutrophils in BALF
  4. cPaucigranulocytic (P), < 2% of eosinophils and < 3% neutrophils in BALF
  5. dIQR, interquartile range; asthma severity stages according to GINA (Global Initiative for Asthma) classification